Everist Genomics Announces External Validation Of OncoDefender™-CRC Test For Predicting Recurrence Risk For Stage I And II Colorectal Cancer Pat

Sunday, January 23rd, 2011

Everist Genomics, a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence, announced the positive results of the first external validation study of its OncoDefender-CRC colorectal cancer recurrence test. The study is being conducted by Mayo Validation Support Services, and is being coordinated with ...

Hamdan Award For Medical Research In The Field Of Osteoporosis Awarded To John A. Kanis

Friday, December 31st, 2010

Professor John A. Kanis is the winner of the 2010 Hamdan Award for Medical Research Excellence in the field of osteoporosis. The prestigious Award honours his outstanding contribution to the development and validation of a widely used fracture risk assessment tool (WHO Fracture Risk Assessment Tool, or FRAX®). The Hamdan ...

Sequenom CMM Commences Pivotal Clinical Validation Study For Its SensiGene Trisomy 21 Laboratory Developed Test

Wednesday, December 29th, 2010

Sequenom, Inc. (Nasdaq: SQNM) announced that the company's wholly-owned reference laboratory, the Sequenom Center for Molecular Medicine (Sequenom CMM), has authorized commencement of a pivotal clinical validation study. This validation study is designed to evaluate the clinical performance of the SensiGene T21 Laboratory Developed Test (LDT) for the detection of ...

Honing Colonoscopy Skills With New Assessment Tool Developed For Trainees

Sunday, December 19th, 2010

Researchers at the Mayo Clinic in Rochester, Minn., have developed a new skills assessment tool for colonoscopy trainees. A report outlining the development and validation of the Mayo Colonoscopy Skills Assessment Tool (MCSAT), designed for the assessment of cognitive and motor skills during colonoscopy training, appears in the December issue ...

“Hidden Kidney Damage” Behind Hypertension Revealed By A Large-scale Survey–Results Of An AVA-E Study On About 9,000 Hypertensive Patients In Japan-

Thursday, December 2nd, 2010

Dainippon Sumitomo Pharma Co., Ltd. (Head Office; Osaka Japan: President; Masayo Tada) conducted a large-scale nationwide survey for the first time in Japan to figure out the actual state of "hidden kidney damage" latent in hypertension. In this survey, called an AVA-E study (albuminuria validation analysis-epidemiological study), about 9,000 hypertensive ...